Toxicology Report

Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -

Nepafenac

What is Nepafenac?

CAS No: 78281-72-8

Nepafenac is a pharmacologically or chemically characterised molecule whose biological activity, physicochemical properties, and toxicological profile have been evaluated to establish its health-based exposure limits for pharmaceutical manufacturing. Its molecular structure—defined by NMR, IR, mass spectrometry, and elemental analysis—determines receptor binding, metabolic transformation pathways, and chemical reactivity relevant to both therapeutic utility and toxicological risk assessment. ADME parameters including oral bioavailability, plasma protein binding, volume of distribution, and metabolic clearance inform toxicokinetic modelling applied during PDE derivation.

The severe toxicity modifier F4 in PDE derivation for Nepafenac is applied when the nature of the critical adverse effect warrants additional conservatism beyond the default interspecies and intraspecies uncertainty factors.

To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
9,000+
Toxicological & Exposure
Assessment Reports Delivered
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Toxicologists
3
Certification Bodies:
ERT · UKRT · DABT

Assessment Methodology

Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.

EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)

Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.

PIC/S – Shared Facilities and Contamination Control Guidance

Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.

ICH Q9 – Quality Risk Management

Provides a structured methodology for risk identification, assessment, control, communication, and review.

ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)

Applied for compounds with potential mutagenic or genotoxic concerns.

Risk-Based Toxicological Assessment

Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.

Weight-of-Evidence (WoE) Approach

Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.

Report Preparation Process

Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.

01

Comprehensive Data Review

Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.

02

Scientific Evaluation

Identification of critical endpoints and selection of appropriate exposure limits.

03

PDE / HBEL Derivation

Transparent and scientifically justified calculations aligned with global toxicological principles.

04

Ex-Agency Expert Review (Our Differentiator)

Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.

05

Final Report Delivery

Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).

Why Masuu Global?

Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.

✓

Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.

✓

Inspection-ready reports — scientifically defensible and audit-prepared from day one.

✓

Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).

✓

Practical implementation recommendations that translate science into actionable contamination control.

✓

Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.

✓

Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.

Frequently Asked Questions

Nepafenac is a non-steroidal anti-inflammatory prodrug used in ophthalmic suspensions to manage pain and inflammation after cataract surgery, and it is converted in eye tissues to the active metabolite amfenac. A toxicological assessment supports exposure limits and carryover control when it is handled as an active ingredient.

A PDE or ADE sets a health-based limit on daily exposure to Nepafenac from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.

A toxicological assessment characterizes the potential health hazards of Nepafenac using the available data. It supports scientifically justified exposure limits, helps manufacturers choose proportionate handling and containment measures, and gives a documented basis for protecting workers and preventing cross-contamination in shared facilities.

Active ingredients can produce effects at doses far below those that cause classical toxicity. In the assessment, anti-inflammatory (NSAID) activity can be reviewed with therapeutic and non-clinical findings to decide which effect should set the limit. This helps ensure the PDE or OEL reflects the most relevant concern for exposed people.

Clinical and therapeutic dose information can be a useful anchor because it reflects effects seen in people. When available, it may support the choice of critical effect and adjustment factors, but it is considered together with non-clinical data, and any limitations in the dose information are stated in the report.

An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.

An OEB places Nepafenac in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.

It can. Fine powders and dust-generating operations may raise inhalation concerns, while solutions or granulated material can change how exposure occurs and which controls are suitable. The assessment should therefore state the form considered, such as powder, solution or granulated material, and explain how it affects the exposure scenario and recommendations.

Three triggers are common: new data on the substance, a change in how it is used or handled, and updated guidance from authorities. When any of these occurs, the earlier conclusions and assumptions should be re-examined and the documentation updated so that the limit stays scientifically justified.

A Masuu Global report sets out the scientific rationale, the calculations and clear recommendations for the substance. It is prepared by certified toxicologists and designed to be regulatory-ready, so the reasoning behind each value can be followed and reviewed. You can ask for it through the Request Your Assessment option on the page.

Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.

Use the Request Your Assessment option on this page and add Nepafenac to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.

Book a Demo